The 'Dispatched' Week in Review Podcast - 4 October

This is a preview of subscriber content

Subscribe now to continue reading.

A significant structural change in the PBS, which the Government attempted to blunt with 60-day dispensed quantities, is arguably the main growth driver in spending on the program. We discuss the change, which along with others, represents a major reversal in a decades-long approach to medicines access. …

Subscribe now to continue reading.

The 'Dispatched' Week in Review Podcast - 4 October

This is a preview of subscriber content

Latest Video

Most Read

Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product

Former minister joins DBG Health board as company broadens healthcare ambition

Medicines Australia appoints former AbbVie executive to key leadership role

US childhood vaccine move away from combinations contrasts with Australia’s national schedule

Patients welcome the timely PBS listing of rare cancer therapy

New Stories

An institution dominated by very clever people, but where is the wisdom?

A plain language version of these dreadful and useless documents

CUREator+ backs six Australian startups with $13.5 million to advance new health technologies

Medicines Australia appoints former AbbVie executive to key leadership role

VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea

Survey exposes deep gaps in neurological care across Australia

Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product

Sign In

The 'Dispatched' Week in Review Podcast - 4 October

This is a preview of subscriber content

Latest Video

Most Read

Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product

Former minister joins DBG Health board as company broadens healthcare ambition

Medicines Australia appoints former AbbVie executive to key leadership role

US childhood vaccine move away from combinations contrasts with Australia’s national schedule

Patients welcome the timely PBS listing of rare cancer therapy

Follow Us

New Stories

An institution dominated by very clever people, but where is the wisdom?

A plain language version of these dreadful and useless documents

CUREator+ backs six Australian startups with $13.5 million to advance new health technologies

Medicines Australia appoints former AbbVie executive to key leadership role

VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea

Survey exposes deep gaps in neurological care across Australia

Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product